Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Anti-TNF agents for the treatment of psoriasis
Leon H. Kircik
, James Q. Del Rosso
Research output
:
Contribution to journal
›
Article
›
peer-review
67
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anti-TNF agents for the treatment of psoriasis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Psoriasis Treatment
100%
Psoriasis
100%
Anti-TNF Agents
100%
Combination Therapy
28%
Biological Agents
28%
Phototherapy
28%
Quality of Life
14%
National Institutes of Health
14%
Clinical Trials
14%
Malignancy
14%
Congestive Heart Failure
14%
Severe Disease
14%
Multisystem
14%
Tumor Necrosis Factor-α
14%
Pharmacologic
14%
Treatment Strategy
14%
Systemic Therapy
14%
Clinical Data
14%
Plaque Psoriasis
14%
Cyclosporine
14%
Moderate to Severe
14%
Safety Considerations
14%
Clinical Practice
14%
Tolerability
14%
Monotherapy
14%
Armamentarium
14%
Overall Health
14%
Safety Data
14%
Mild Disease
14%
Response Rate
14%
Psoriatic Arthritis
14%
Infliximab
14%
Systemic Disease
14%
Immune Mediators
14%
Symptom Relief
14%
Adalimumab
14%
Lack of Response
14%
Etanercept
14%
Traditional Agents
14%
Topical Treatment
14%
FDA-approved Drugs
14%
Immunological Mechanisms
14%
Total Annual Cost
14%
Data Interpretation
14%
Topical Agents
14%
Cytopenia
14%
TNF-α Antagonists
14%
Acitretin
14%
Cutaneous Symptoms
14%
Targeted Phototherapy
14%
Demyelinating Disease
14%
Adverse Event Profiles
14%
Lupus-like
14%
Nursing and Health Professions
Psoriasis
100%
Tumor Necrosis Factor Inhibitor
100%
Diseases
55%
Phototherapy
33%
Accident Prevention
33%
Combination Therapy
22%
Tumor Necrosis Factor
22%
Adverse Event
11%
National Health Organization
11%
Infection
11%
Clinical Practice
11%
Monotherapy
11%
Congestive Heart Failure
11%
Food and Drug Administration
11%
Systemic Therapy
11%
Adalimumab
11%
Ciclosporin
11%
Topical Agent
11%
Psoriasis Vulgaris
11%
Topical Treatment
11%
Infliximab
11%
Etanercept
11%
Demyelinating Disease
11%
Systemic Disease
11%
Cytopenia
11%
Etretin
11%
Lupus Like Syndrome
11%
Efficacy
11%
Quality of Life
11%
Clinical Trial
11%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Tumor Necrosis Factor Inhibitor
100%
Diseases
55%
Tumor Necrosis Factor
22%
Combination Therapy
22%
Adverse Event
11%
Monotherapy
11%
Congestive Heart Failure
11%
Clinical Trial
11%
Infection
11%
Psoriasis Vulgaris
11%
Tolerability
11%
Infliximab
11%
Adalimumab
11%
Ciclosporin
11%
Etanercept
11%
Topical Agent
11%
Etretin
11%
Systemic Disease
11%
Cytopenia
11%
Demyelinating Disease
11%
Lupus Like Syndrome
11%